Clinical behavior and outcome of papillary T1 thyroid cancers: South Korea vs. Turkey vs. Colombia. A cohort study analyzing oncological outcomes.

Abstract

BACKGROUND/PURPOSE\nThere has not been an international multicentric study to examine the relationship between thyroid cancer clinical outcomes and geographic location for South Korea, Colombia, and Turkey, whereas thyroid cancer is amongst the highest three cancer types seen in South Korea and Turkey. The aim of the study was to assess regional differences of T1 papillary thyroid cancer outcomes in Korea, Turkey and Colombia.\n\n\nMETHODS\nThis is an observational non-randomized study. A total of 2720 patients who have been operated for T1 papillary thyroid cancer between 2011 and 2014 and are on routine follow-up have been recruited. The mean follow-up was 46.4\xa0±\xa010.7 months. Data were collected in a commonly used database and analyses were conducted.\n\n\nRESULTS\nPatients participated in South Korea (88.2%), Turkey (9.1%) and Colombia (2.6%). Eighty percent were female. Female dominance tended to be higher in Colombia (p\xa0=\xa00.01). Mean age at diagnosis was 45.2 years. There was no mortality. Recurrence tended to be higher in Colombia (p\xa0<\xa00.001). Moreover, statistical analysis revealed differences among patients regarding symptoms (p\xa0<\xa00.001), family history (p\xa0<\xa00.001), euthyroidism (p\xa0<\xa00.001), anti-Tg and/or anti-TPO positivity (p\xa0<\xa00.001), FNAB results (p\xa0<\xa00.001), type of resection (p\xa0<\xa00.001), prophylactic central node dissection (p\xa0<\xa00.001), tumor size (p\xa0<\xa00.001), multifocality (p\xa0<\xa00.001), bilaterality (p\xa0<\xa00.001), tumor subtype (p\xa0<\xa00.001) and radioactive iodine treatment (p\xa0<\xa00.01).\n\n\nCONCLUSION\nThyroid cancer is becoming more commonly diagnosed worldwide. This international multicentric study has identified differences in disease presentation, treatment approaches and outcome, which need to be investigated, especially by increasing the number of participating countries. Future comparisons will facilitate developments in treatment for the benefit of patient outcomes.